01—Abstract
Summary
Summary of the 10-Q filed May 9, 2024. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated reported a net loss of $157.1 milliona for the three months ended March 31, 2024, compared with $159.8 million in the same period of 2023.
Product revenues, net, rose to $75.5 millionb from $65.2 million, an increase the filing states as 15.8%, driven by ARIKAYCE sales in the US, Japan, and Europe and the rest of the world. Operating expenses included R&D of $121.1 million and SG&A of $93.1 million, the latter up $13.2 million, primarily from compensation, stock-based compensation, and commercial readiness activities for brensocatib. Net cash used in operating activities was $184.0 million.
Cash and cash equivalents were $595.7 millionc at March 31, 2024, up from $482.4 million at December 31, 2023, mainly because $300.0 million of marketable securities matured during the quarter. Working capital was $337.9 million, down from $703.4 million at year-end 2023. Total shareholders' deficit was $464.8 million.
The company stated it has sufficient funds for at least the next 12 months, but it expects future cash requirements to be substantial and may raise additional capital. In the first quarter of 2024 it entered into a new at-the-market equity program of up to $500.0 milliond, under which no shares had been sold as of the filing date. The filing highlights several near-term catalysts.
Topline data from the Phase 3 ASPEN trial of brensocatib in bronchiectasis are anticipated in the latter half of the second quarter of 2024, and the company reported topline safety and certain exploratory efficacy data from the Phase 2 TPIP study in PH-ILD in May 2024. The 2025 convertible notes ($224.2 million carrying value) are classified as current, which makes the current portion of long-term debt a near-term obligation.
02—Key points
Key Highlights
- Net loss of $157.1 million for Q1 2024 versus $159.8 million in Q1 2023; basic and diluted net loss per share of $(1.06) versus $(1.17).
- Product revenues, net of $75.5 million, up from $65.2 million, an increase of 15.8%; US revenues were $56.3 million, Japan $14.9 million, and Europe and rest of world $4.3 million.
- Cash and cash equivalents of $595.7 million at March 31, 2024, up from $482.4 million at December 31, 2023, after $300.0 million of marketable securities matured.
- Net cash used in operating activities of $184.0 million for the quarter, compared with $146.3 million a year earlier.
- Total shareholders' deficit of $464.8 million; total liabilities of $1.62 billion against total assets of $1.16 billion.
- Debt includes $789.7 million of convertible notes (including $224.2 million of 2025 notes classified as current), a $373.5 million Term Loan, and a $157.0 million Royalty Financing Agreement carrying value.
- Pipeline catalysts: ASPEN topline brensocatib data expected in the latter half of Q2 2024; TPIP Phase 2 PH-ILD topline safety and exploratory efficacy data reported in May 2024; ENCORE topline data anticipated in 2025.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 9, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $75.50M$65.21M | +15.8% |
| Cost of Revenue | $17.46M$13.83M | +26.2% |
| Gross Profit | $58.04M$51.38M | +13.0% |
| R&D Expenses | $121.08M$127.86M | −5.3% |
| SG&A Expenses | $93.10M— | — |
| Operating Expenses | $221.00M$213.37M | +3.6% |
| Operating Income | -$145.50M-$148.16M | +1.8% |
| Interest Expense | $21.04M$20.00M | +5.2% |
| Net Income | -$157.09M-$159.76M | +1.7% |
| EPS (Basic) | $-1.06$-1.17 | +9.4% |
| EPS (Diluted) | $-1.06$-1.17 | +9.4% |
| Shares Outstanding (Basic) | 148.46M136.35M | +8.9% |
| Shares Outstanding (Diluted) | 148.46M136.35M | +8.9% |
05—Questions
Frequently Asked Questions
How did ARIKAYCE sales perform in the first quarter of 2024?
Product revenues, net, were $75.5 million for the three months ended March 31, 2024, up from $65.2 million a year earlier, an increase the filing states as 15.8%. Growth came from the US ($56.3 million, up 14.8%), Japan ($14.9 million, up 13.2%), and Europe and the rest of the world ($4.3 million, up 42.4%).
What is the company's liquidity position and does it need more capital?
Cash and cash equivalents were $595.7 million at March 31, 2024, and working capital was $337.9 million, down from $703.4 million at December 31, 2023. The company states it currently has sufficient funds for at least the next 12 months, but expects its future cash requirements to be substantial and may raise additional capital. A new at-the-market program of up to $500.0 million was established in Q1 2024, and no shares had been sold under it during the quarter.
What are the company's main debt obligations?
As of March 31, 2024, the company had $800.0 million face value of convertible notes (carrying value of $789.7 million, including the 2025 notes of $224.2 million classified as current), a Term Loan with a carrying value of $373.5 million, and a Royalty Financing Agreement with OrbiMed carried at $157.0 million. Under the royalty agreement, OrbiMed receives royalties of 4% of ARIKAYCE global net sales before September 1, 2025, and 4.5% thereafter, plus 0.75% of brensocatib global net sales if approved.
What clinical milestones are expected next?
Topline data from the Phase 3 ASPEN trial of brensocatib in bronchiectasis are anticipated in the latter half of the second quarter of 2024. The company reported topline safety data and certain exploratory efficacy endpoints from the Phase 2 TPIP study in PH-ILD in May 2024, and plans to discuss a Phase 3 design with regulators with initiation anticipated in 2025. ENCORE topline data for ARIKAYCE are anticipated in 2025.
Why did operating expenses change compared with the prior year?
R&D expenses decreased $6.8 million to $121.1 million, primarily because a $10.3 million non-cash asset acquisition cost for Vertuis was recorded in Q1 2023, partially offset by higher compensation and stock-based compensation. SG&A expenses increased $13.2 million to $93.1 million, primarily from higher compensation and stock-based compensation and a $4.7 million increase in professional fees driven by commercial readiness activities for brensocatib.
06—Continue